Overview

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a single center, open label, randomized, parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of obeticholic acid (OCA).
Phase:
Phase 1
Details
Lead Sponsor:
Intercept Pharmaceuticals
Treatments:
Chenodeoxycholic Acid